Press Releases

November 6, 2019
Ocugen Announces Warrant Restructuring
Reduced Series C warrant shares to 20 million from 50 million MALVERN, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc. , (NASDAQ: OCGN), a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and
Additional Formats
October 23, 2019
Ocugen Appoints Jessica Crespo, CPA, as Controller
MALVERN, Pa., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc. , (NASDAQ: OCGN), a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases, today announced the appointment of
Additional Formats
October 9, 2019
Ocugen Announces Share Repurchase Program
MALVERN, Pa., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc. , (NASDAQ: OCGN) today announced that its Board of Directors unanimously approved a share repurchase program authorizing the repurchase of up to $2 million in value of its outstanding common stock.  Ocugen believes its shares are
Additional Formats
October 7, 2019
Ocugen Announces Amendment to Asset Purchase Agreement
Restructured terms increase value to Ocugen MALVERN, Pa., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc. , (NASDAQ: OCGN) a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye
Additional Formats
October 1, 2019
Ocugen Appoints Sanjay S. Subramanian, MBA, as Chief Financial Officer
MALVERN, Pa., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc. , (NASDAQ: OCGN), a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases, today announced the appointment of
Additional Formats
September 30, 2019
Ocugen to Present at Three Upcoming Conferences
MALVERN, Pa., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc. , (NASDAQ: OCGN) a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases, today announced that Shankar Musunuri,
Additional Formats
Displaying 1 - 10 of 14